Yarrow Bioscience (YARW) FY2025 10-K Risk Factors: 21 New, 11 Dropped

What the changes say

Yarrow is merging with VYNE, resulting in massive dilution where pre-merger VYNE holders retain only 3 percent ownership.

What changed since the prior 10-K

New

NewRisks Related to the Proposed Merger
Failure to complete, or delays in completing, the potential Merger with Yarrow could materially and adversely affect VYNE's results of operations, business, financial results and/or common stock price
The pending merger with Yarrow may be delayed or fail to close, disrupting VYNE's business and stock price.
NewRisks Related to the Proposed Merger
VYNE and Yarrow may mutually agree to waive the condition to the Merger requiring approval for listing on Nasdaq Stock Market ("Nasdaq"), and if such condition is waived, the Combined Company’s stock may not be listed on Nasdaq following completion of the Merger
The merger may proceed without Nasdaq listing approval for the combined company's stock if the condition is waived.
NewRisks Related to the Proposed Merger
The Exchange Ratio for the Merger will not change or otherwise be adjusted based on the market price of VYNE common stock
The exchange ratio of 35.8667 Yarrow shares per VYNE share is fixed and will not adjust based on VYNE's stock price.
NewRisks Related to the Proposed Merger
The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes
The merger can be forced to close despite industry-wide changes or economic downturns causing a material adverse effect.
NewRisks Related to the Proposed Merger
If the Merger is not completed, VYNE's stock price may decline significantly
VYNE's stock price may decline significantly if the merger fails to be completed.
NewRisks Related to the Proposed Merger
If we complete the Merger, the Combined Company will need to raise additional capital, including by potentially issuing equity securities or incurring debt, which may cause significant dilution to the Combined Company’s stockholders or restrict the Combined Company’s operations
A $100.0 million pre-closing financing and future capital raises will significantly dilute existing stockholders and restrict operations.
NewRisks Related to the Proposed Merger
Additional financing may not be available to the Combined Company, when we need it or may not be available on favorable terms
Additional debt or equity financing may carry restrictive covenants or unfavorable licensing terms.
NewRisks Related to the Proposed Merger
Some of Yarrow’s and VYNE's directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests
Directors and executive officers have personal financial interests in the merger, such as retention bonuses and accelerated equity.
NewRisks Related to the Proposed Merger
The VYNE stockholders and the stockholders of Yarrow may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Yarrow common stock issued in the Yarrow Pre-Closing Financing
Stockholders may experience substantial ownership dilution without receiving commensurate strategic benefits from the merger.
NewRisks Related to the Proposed Merger
VYNE securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Combined Company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies
Former VYNE securityholders will own only 3.0 percent of the combined company, while former Yarrow holders will own 97.0 percent.
NewRisks Related to the Proposed Merger
Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement
Anti-takeover provisions in the merger agreement discourage third parties from submitting competing acquisition proposals.
NewRisks Related to the Proposed Merger
Because the lack of a public market for Yarrow common stock makes it difficult to evaluate the fair market value of its capital stock, the value of VYNE common stock to be issued to Yarrow stockholders may be more or less than the fair market value of Yarrow common stock
Because Yarrow is privately held, the fair market value of its stock is difficult to evaluate relative to the shares issued.
NewRisks Related to the Proposed Merger
Lawsuits may be filed against us, Yarrow, or any of the members of our or Yarrow's boards of directors arising out of the Merger, which may delay or prevent the Merger
NewRisks Related to the Proposed Merger
VYNE has never paid cash dividends on any of its capital stock. Other than in connection with the Merger, VYNE does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future
NewRisks Related to the Proposed Merger
VYNE will not have any right to make damage claims against Yarrow for the breach of any representation, warranty or covenant made by Yarrow in the Merger Agreement
NewRisks Related to the Proposed Reverse Stock Split
The reverse stock split may not increase the Combined Company’s stock price over the long-term
NewRisks Related to the Proposed Reverse Stock Split
The reverse stock split may decrease the liquidity of the Combined Company common stock
NewRisks Related to the Proposed Reverse Stock Split
The reverse stock split may lead to a decrease in the Combined Company’s overall market capitalization
NewRisks Related to Development of Our Current Product Candidates
We may be delayed in commencing or conducting our clinical trials, or we may be prevented from completing our clinical trials, if the FDA, or other applicable regulatory authority, finds deficiencies or requests additional information with respect to our INDs
NewRisks Related to Development of Our Current Product Candidates
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects
NewRisks Related to Our Financial Position and Need for Capital
Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products could impair our ability to grow our business

Dropped

DroppedRisks Related to Development of Our Product Candidates
Our business is substantially dependent on the successful development of our BET inhibitor product candidates
Dependence on BET inhibitor product candidates repibresib gel and VYN202.
DroppedRisks Related to Development of Our Product Candidates
If we experience delays in the completion of, or if we terminate, any of our future clinical trials, our business, financial condition, operating results and prospects would be adversely affected
DroppedRisks Related to Development of Our Product Candidates
could negatively impact us by reducing revenues or increasing expenses, and cause the product not to be commercially viable. Absence of long-term safety data may further limit the approved uses of products
DroppedRisks Related to Our Financial Position and Need for Capital
We may in-license, acquire and develop additional product candidates. The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical product candidates, negotiate licensing or acquisition agreements with their current owners and finance these arrangements
Clinical trial delays and systemic BET inhibitor tolerability issues.
DroppedRisks Related to Our Financial Position and Need for Capital
systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program
DroppedRisks Related to Government Regulation
penalties, contractual damages, reputational harm, and diminished profits and future earnings. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business
DroppedRisks Related to Government Regulation
increase in the amount of rebates that manufacturers pay for coverage of their drugs by Medicaid programs may have an adverse effect on us. It is uncertain how current and future reforms in these areas will influence the future of our business operations and financial condition
DroppedRisks Related to Government Regulation
We and our contract manufacturers are subject to significant regulation with respect to manufacturing of our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity
DroppedRisks Related to Our Intellectual Property
intellectual property rights or may infringe upon our intellectual property rights, including through means that may be difficult to prevent or detect
DroppedRisks Related to the Ownership of Our Common Stock
such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful
DroppedRisks Related to the Ownership of Our Common Stock
that we incur substantial additional professional fees and internal costs within our accounting and finance functions and that we expend significant management efforts

Reworded

91% rewrittenRisks Related to Government Regulation
Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market, and distribute our products after clearance or approval is obtained
Added mention of the current administration pursuing policies to reduce regulations and expenditures across HHS, FDA, and CMS.
88% rewrittenRisks Related to Development of Our Current Product Candidates
Even if our product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates
Added specific risks regarding post-approval trials, REMS, commercial viability, and narrower FDA-approved patient populations.
81% rewrittenRisks Related to the Ownership of Our Common Stock
Our directors and executive officers may be subject to litigation for a variety of claims or disputes. Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law
Added specific Delaware law criteria regarding good faith and unlawful conduct for officer and director indemnification.
80% rewrittenRisks Related to Development of Our Current Product Candidates
We may encounter delays in enrolling patients and successfully completing clinical trials for our product candidates and may be delayed in, or prevented from, commencing or completing such trials due to factors that are largely beyond our control
Changed clinical trial 'aborted' to 'terminated'.
Was: We may encounter delays in enrolling patients and successfully completing clinical trials for our product candidates and may be delayed in, or prevented from, commencing such trials due to factors that are largely beyond our control
73% rewrittenRisks Related to the Ownership of Our Common Stock
If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
Added that internal controls compliance requires substantial professional fees, internal costs, and management efforts.
65% rewrittenRisks Related to the Ownership of Our Common Stock
We incur significant costs and demands upon management as a result of being a public company
Clarified ongoing public company legal, accounting, and compliance costs under changing SEC and Nasdaq regulations.
64% rewrittenRisks Related to Our Financial Position and Need for Capital
We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards
Updated net operating loss carryforwards figures to $332.1 million federal and $94.2 million state as of December 31, 2025.
59% rewrittenRisks Related to Government Regulation
Healthcare reforms by governmental authorities and related reductions in pharmaceutical pricing, reimbursement and coverage by third party payors may adversely affect our business
Retained healthcare reform and reimbursement risk language with minor stylistic framing.
54% rewrittenRisks Related to Our Financial Position and Need for Capital
Supply interruptions may disrupt the availability of our product candidates and cause delays in conducting preclinical or clinical activities
52% rewrittenRisks Related to Our Intellectual Property
We may not obtain intellectual property rights or otherwise be able to protect our intellectual property rights throughout the world
39% rewrittenRisks Related to Government Regulation
In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws
37% rewrittenRisks Related to Our Financial Position and Need for Capital
We may decide not to continue developing any of our product candidates at any time during development or of any of our products after approval, which would reduce or eliminate our potential return on investment for those product candidates or products
36% rewrittenRisks Related to Development of Our Current Product Candidates
Results obtained in preclinical studies and completed clinical trials may not predict success in later clinical trials
35% rewrittenRisks Related to Our Financial Position and Need for Capital
The Israeli Tax Authority may disagree with our conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits
34% rewrittenRisks Related to Our Financial Position and Need for Capital
We may become subject to lawsuits or investigations that could have a material adverse impact on our business, results of operations and financial condition
31% rewrittenRisks Related to Our Financial Position and Need for Capital
We have incurred significant losses since our inception and we anticipate that we will continue to incur significant losses for the foreseeable future, which could harm our future business prospects
30% rewrittenRisks Related to Our Intellectual Property
We may not be able to enforce covenants not to compete under applicable employment laws
28% rewrittenRisks Related to Our Financial Position and Need for Capital
If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully execute our strategy
27% rewrittenRisks Related to Development of Our Current Product Candidates
The development of these new chemical entities carries even greater risk and a higher probability of failure. Our failure to successfully develop our product candidates will have a material adverse effect on our business and financial condition

All 76 risk factors

Headings as the filing states them, in filing order.

Risks Related to the Proposed Merger

01Failure to complete, or delays in completing, the potential Merger with Yarrow could materially and adversely affect VYNE's results of operations, business, financial results and/or common stock priceNew
02VYNE and Yarrow may mutually agree to waive the condition to the Merger requiring approval for listing on Nasdaq Stock Market ("Nasdaq"), and if such condition is waived, the Combined Company’s stock may not be listed on Nasdaq following completion of the MergerNew
03The Exchange Ratio for the Merger will not change or otherwise be adjusted based on the market price of VYNE common stockNew
04The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causesNew
05If the Merger is not completed, VYNE's stock price may decline significantlyNew
06If we complete the Merger, the Combined Company will need to raise additional capital, including by potentially issuing equity securities or incurring debt, which may cause significant dilution to the Combined Company’s stockholders or restrict the Combined Company’s operationsNew
07Additional financing may not be available to the Combined Company, when we need it or may not be available on favorable termsNew
08Some of Yarrow’s and VYNE's directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interestsNew
09The VYNE stockholders and the stockholders of Yarrow may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Yarrow common stock issued in the Yarrow Pre-Closing FinancingNew
10VYNE securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the Combined Company following the completion of the Merger as compared to their current ownership and voting interests in the respective companiesNew
11Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger AgreementNew
12Because the lack of a public market for Yarrow common stock makes it difficult to evaluate the fair market value of its capital stock, the value of VYNE common stock to be issued to Yarrow stockholders may be more or less than the fair market value of Yarrow common stockNew
13Lawsuits may be filed against us, Yarrow, or any of the members of our or Yarrow's boards of directors arising out of the Merger, which may delay or prevent the MergerNew
14VYNE has never paid cash dividends on any of its capital stock. Other than in connection with the Merger, VYNE does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable futureNew
15VYNE will not have any right to make damage claims against Yarrow for the breach of any representation, warranty or covenant made by Yarrow in the Merger AgreementNew

Risks Related to the Proposed Reverse Stock Split

16The reverse stock split may not increase the Combined Company’s stock price over the long-termNew
17The reverse stock split may decrease the liquidity of the Combined Company common stockNew
18The reverse stock split may lead to a decrease in the Combined Company’s overall market capitalizationNew

Risks Related to Development of Our Current Product Candidates

19The development of these new chemical entities carries even greater risk and a higher probability of failure. Our failure to successfully develop our product candidates will have a material adverse effect on our business and financial condition27% rewritten
20We may encounter delays in enrolling patients and successfully completing clinical trials for our product candidates and may be delayed in, or prevented from, commencing or completing such trials due to factors that are largely beyond our control80% rewritten
21We may be delayed in commencing or conducting our clinical trials, or we may be prevented from completing our clinical trials, if the FDA, or other applicable regulatory authority, finds deficiencies or requests additional information with respect to our INDsNew
22International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
23New chemical entities may require more time and resources for development, testing and regulatory approval
24Results obtained in preclinical studies and completed clinical trials may not predict success in later clinical trials36% rewritten
25Top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as additional data become available and are subject to audit and verification procedures that could result in material changes in the final data
26We have a limited history as a clinical-stage biopharmaceutical company developing product candidates for immuno-inflammatory conditions, which may make it difficult to assess our future viability
27We may spend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
28We have not obtained regulatory approvals to market our product candidates, and we may be delayed in obtaining or fail to obtain such regulatory approvals and to commercialize these product candidates
29Even if our product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates88% rewritten
30We have historically relied on third parties to conduct, supervise and monitor our clinical trials, and if these third parties perform in an unsatisfactory manner, it may harm our business
31Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays

Risks Related to Our Financial Position and Need for Capital

32We will need substantial additional funding to pursue our business objectives if the Merger is not completed. If we are unable to raise capital when needed, we could be forced to curtail our planned operations
33We have incurred significant losses since our inception and we anticipate that we will continue to incur significant losses for the foreseeable future, which could harm our future business prospects31% rewritten
34SEC regulations limit the amount of funds we can raise during any 12-month period pursuant to our shelf registration statement on Form S-3
35Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish proprietary rights
36Collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates
37In addition, the success of future collaboration arrangements that we may enter into will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations
38We are subject to various risks and uncertainties arising out of the completed divestiture of our commercial business, any of which could materially and adversely affect our business and operations, and our stock price
39Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products could impair our ability to grow our businessNew
40If the Merger is not consummated, we may engage in strategic transactions, which could impact our liquidity, increase our expenses and present significant distractions to our management
41We may decide not to continue developing any of our product candidates at any time during development or of any of our products after approval, which would reduce or eliminate our potential return on investment for those product candidates or products37% rewritten
42Supply interruptions may disrupt the availability of our product candidates and cause delays in conducting preclinical or clinical activities54% rewritten
43We might not be able to utilize a significant portion of our net operating loss carryforwards and research and development tax credit carryforwards64% rewritten
44The Israeli Tax Authority may disagree with our conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits35% rewritten
45If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully execute our strategy28% rewritten
46We may become subject to lawsuits or investigations that could have a material adverse impact on our business, results of operations and financial condition34% rewritten
47Our employees, independent contractors, principal investigators, consultants, vendors, CROs and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our business
48Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations

Risks Related to Government Regulation

49In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws39% rewritten
50Healthcare reforms by governmental authorities and related reductions in pharmaceutical pricing, reimbursement and coverage by third party payors may adversely affect our business59% rewritten
51Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market, and distribute our products after clearance or approval is obtained91% rewritten
52We are subject to various U.S. and foreign anti-bribery and anti-corruption laws, and any violations by us of such laws could result in substantial penalties
53Our business involves the use of hazardous materials and we and our third party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business
54Sanctions and other trade control laws create the potential for significant liabilities, penalties and reputational harm

Risks Related to Our Intellectual Property

55If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to any of our product candidates are not adequate, we may not be able to compete effectively and we otherwise may be harmed
56We have in-licensed intellectual property necessary to develop our BET inhibitor product candidates, and if we fail to comply with our obligations under any of these arrangements, we could lose such intellectual property rights
57Changes in U.S. or foreign patent law and practice could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
58If we infringe or are alleged to infringe or otherwise violate intellectual property rights of third parties, our business could be harmed
59If we are unable to secure trademark registrations, secure appropriate domain names and protect our trademarks or trade dress from infringement, our business prospects may be harmed
60We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming
61An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing
62We may not obtain intellectual property rights or otherwise be able to protect our intellectual property rights throughout the world52% rewritten
63We may not be able to enforce covenants not to compete under applicable employment laws30% rewritten

Risks Related to the Ownership of Our Common Stock

64The trading price of the shares of our common stock is volatile, and stockholders could incur substantial losses
65Provisions in our corporate charter documents and under Delaware law may prevent or frustrate attempts by our stockholders to change our management and hinder efforts to acquire a controlling interest in us, and the market price of our common stock may be lower as a result
66In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial
67Our directors and executive officers may be subject to litigation for a variety of claims or disputes. Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law81% rewritten
68Our amended and restated certificate of incorporation and our amended and restated bylaws contain exclusive forum selection clauses, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees
69We are eligible to report as a “smaller reporting company,” and as a result of the reduced reporting requirements applicable to such companies, our securities may be less attractive to investors
70An active public market for our common stock may not be sustained
71If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline
72Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
73We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation in the price of our common stock
74If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired73% rewritten
75We incur significant costs and demands upon management as a result of being a public company65% rewritten
76We are subject to risks related to climate change in the long term

Other Yarrow Bioscience 10-Ks

FY2024 10-K risk factors
66 risks
Clinical-stage biotechnology company dependent on the development of BET inhibitor product candidates repibresib gel and VYN202. Accumulated deficit of $731.2 million with net losses of $39.8 million in 2024. Subject to baby shelf rules limiting capital raising under Form S-3.
Filed Mar 06, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.